These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 19003994)

  • 1. Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy.
    Wenske S; Korets R; Cronin AM; Vickers AJ; Fleisher M; Scher HI; Pettersson K; Guillonneau B; Scardino PT; Eastham JA; Lilja H
    Int J Cancer; 2009 Feb; 124(3):659-63. PubMed ID: 19003994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
    Steuber T; Vickers AJ; Haese A; Becker C; Pettersson K; Chun FK; Kattan MW; Eastham JA; Scardino PT; Huland H; Lilja H
    Int J Cancer; 2006 Mar; 118(5):1234-40. PubMed ID: 16152616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early prediction of prostate cancer biochemical recurrence and identification of disease persistence using PSA isoforms and human kallikrein-2.
    Do Carmo Silva J; Vesely S; Luksanova H; Prusa R; Babjuk M
    Tumour Biol; 2021; 43(1):197-207. PubMed ID: 34486998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Huber A; Lümmen G; Tscholl R
    Urology; 2000 Apr; 55(4):481-5. PubMed ID: 10736487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
    Haese A; Graefen M; Steuber T; Becker C; Pettersson K; Piironen T; Noldus J; Huland H; Lilja H
    Prostate; 2001 Oct; 49(2):101-9. PubMed ID: 11582588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer.
    Steuber T; Vickers AJ; Serio AM; Vaisanen V; Haese A; Pettersson K; Eastham JA; Scardino PT; Huland H; Lilja H
    Clin Chem; 2007 Feb; 53(2):233-40. PubMed ID: 17185368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
    Haese A; Vaisanen V; Lilja H; Kattan MW; Rittenhouse HG; Pettersson K; Chan DW; Huland H; Sokoll LJ; Partin AW
    J Urol; 2005 Mar; 173(3):752-6. PubMed ID: 15711262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam.
    Carlsson S; Maschino A; Schröder F; Bangma C; Steyerberg EW; van der Kwast T; van Leenders G; Vickers A; Lilja H; Roobol MJ
    Eur Urol; 2013 Nov; 64(5):693-9. PubMed ID: 23683475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer.
    Stephan C; Jung K; Nakamura T; Yousef GM; Kristiansen G; Diamandis EP
    Int J Urol; 2006 Mar; 13(3):238-43. PubMed ID: 16643616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kallikrein markers performance in pretreatment blood to predict early prostate cancer recurrence and metastasis after radical prostatectomy among very high-risk men.
    Assel MJ; Ulmert HD; Karnes RJ; Boorjian SA; Hillman DW; Vickers AJ; Klee GG; Lilja H
    Prostate; 2020 Jan; 80(1):51-56. PubMed ID: 31603253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human Kallikrein-2, Prostate Specific Antigen and Free- Prostate Specific Antigen in Combination to Discriminate Prostate Cancer from Benign Diseases in Syrian Patients.
    Bachour DM; Chahin E; Al-Fahoum S
    Asian Pac J Cancer Prev; 2015; 16(16):7085-8. PubMed ID: 26514494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy.
    Steuber T; Vickers A; Haese A; Kattan MW; Eastham JA; Scardino PT; Huland H; Lilja H
    Int J Cancer; 2007 Apr; 120(7):1499-504. PubMed ID: 17205511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy.
    Shariat SF; Gottenger E; Nguyen C; Song W; Kattan MW; Andenoro J; Wheeler TM; Spencer DM; Slawin KM
    Cancer Res; 2002 Oct; 62(20):5974-9. PubMed ID: 12384565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer.
    Haese A; Becker C; Noldus J; Graefen M; Huland E; Huland H; Lilja H
    J Urol; 2000 May; 163(5):1491-7. PubMed ID: 10751864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients.
    Douglas TH; Morgan TO; McLeod DG; Moul JW; Murphy GP; Barren R; Sesterhenn IA; Mostofi FK
    Cancer; 1997 Jul; 80(1):107-14. PubMed ID: 9210715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
    Raaijmakers R; de Vries SH; Blijenberg BG; Wildhagen MF; Postma R; Bangma CH; Darte C; Schröder FH
    Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
    Steuber T; Niemela P; Haese A; Pettersson K; Erbersdobler A; Felix Chun KH; Graefen M; Kattan MW; Huland H; Lilja H
    Prostate; 2005 Apr; 63(1):13-8. PubMed ID: 15378521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
    Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH
    Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative prostate-specific antigen isoform p2PSA ≤ 22.5 pg/ml predicts advanced prostate cancer in patients undergoing radical prostatectomy.
    Eminaga O; Bögemann M; Breil B; Titze U; Wötzel F; Eltze E; Bettendorf O; Semjonow A
    Urol Oncol; 2014 Nov; 32(8):1317-26. PubMed ID: 24893699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parameters derived from the postoperative decline in ultrasensitive PSA improve the prediction of radical prostatectomy outcome.
    Vesely S; Jarolim L; Schmidt M; Minarik I; Dusek P; Babjuk M
    World J Urol; 2013 Apr; 31(2):299-304. PubMed ID: 22684375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.